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Bacterial meningitis is a devastating infectious disease of
the brain that causes persistent neurofunctional deficits
including cerebral palsy, hearing loss, and impairment of
learning and memory in up to half of the surviving chil-
dren. Brain injury to the cortical hemispheres and the hip-
pocampus has been identified as histomorphologic
correlate of neurological sequelae. Using disease models
that exhibit important forms of brain injury found in the
human disease, gene expression profiling in acute, i.e. 6 h
and late disease, i.e. 30 h after initiation of antibiotic ther-
apy, pointed towards mechanisms of brain injury and
regeneration that were evaluated for their functional rele-
vance and therapeutic potential.
Brain damage in the cerebral cortex was found to be asso-
ciated with the occurrence of vasculitis, brain edema,
endothelin induced vasospasms, and subsequent focal
ischemia. In the hippocampus, a brain region involved in
learning and memory function, cells undergo caspase-3
dependent apoptosis primarily affecting immature neu-
rons in the subgranular zone of the dentate gyrus. Genes
found to be significantly regulated in the cortex and the
hippocampus during the acute disease, were predomi-
nantly associated with host immune response and inflam-
mation. In acute diseases, bacteriolysis by antibiotic
therapy triggered an upsurge of inflammatory mediators
including matrix metalloproteinases (MMPs) resulting in
excessive protease activity and degradation of collagen.
Consequently, therapy with inhibitors of MMPs and non-
bacteriolytic antibiotics significantly attenuated cortical
injury. During the later disease phase the transcriptome
remained associated with immune response in the cortex,
while in the hippocampus, the majority of regulated genes
were related to tissue remodelling and neurogenesis. This
was reflected by the documentation of increased cellular
proliferation in the subgranular zone of the hippocampal
dentate gyrus after meningitis. The induction of tissue
repair mechanisms as early as 30 h after the initiation of
antibiotic therapy, suggests that antiproliferative therapies
may be detrimental, while treatment strategies that sup-
port tissue repair and regeneration may be beneficial
when given in addition to antibiotics. Indeed, adjuvant
dexamethasone increased, while trophic support by brain
derived neuroptrophic factor (BDNF) decreased hippoc-
ampal damage. Other strategies to attenuate hippocampal
apoptosis included Vitamin B6 which prevented the
decrease in cellular energy stores in the hippocampus and
the combined inhibition of MMPs and TNF-alpha con-
verting enzyme (TACE) led to improved learning and
memory function. Thus prevention of bacteriolysis, inhi-
bition of MMPs and TACE, trophic support and Vitamin
B6 are among the promising experimental therapies
aimed at attenuation of neurological sequelae from bacte-
rial meningitis.
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